^
Association details:
| Biomarker: | DLL3 overexpression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
Published date:
09/20/2023
Excerpt:
In the ES-SCLC cohort (n = 30), the progression-free survival associated with PE plus anti-PD-L1 antibody was significantly worse in DLL3High cases than in DLL3Low cases (4.7 vs. 7.4 months, P = 0.01).
Secondary therapy:
etoposide oral
DOI:
https://doi.org/10.1038/s41416-023-02427-3
Source:
Title:
Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.
Published date:
05/25/2023
Excerpt:
In ES-SCLC cohort (n = 17), the PFS of PE plus anti-PD-L1 antibody in patients with DLL3High was significantly worse than those in patients with DLL3Low (4.1 months [95% CI, 2.0-6.3] vs. 7.4 months [95% CI, 2.5-12.3]; HR 3.78 [95% CI, 1.1-12.5], p = 0.03).
Secondary therapy:
Chemotherapy + etoposide oral
DOI:
10.1200/JCO.2023.41.16_suppl.8586
